Venetoclax and Tocilizumab for the Treatment of Patients With Relapsed or Refractory t(11;14) Multiple Myeloma

NCT05391750 · clinicaltrials.gov ↗

PHASE1

Phase

ACTIVE_NOT_RECRUITING

Status

7

Enrollment

OTHER

Sponsor class

Conditions

Recurrent Plasma Cell Myeloma
Refractory Plasma Cell Myeloma

Interventions

BIOLOGICAL: Tocilizumab
DRUG: Venetoclax

Sponsor

Emory University

Collaborators

[object Object]